Noncompartmental Analysis
We considered a pharmacokinetic curve nonevaluable if >1 blood sample was hemolyzed, if protocol deviations had occurred that may have affected the pharmacokinetics of the study drugs (such as use of an interacting concomitant medication), or if a participant was nonadherent based on measured drug concentrations for both the anchor drug and TFV. The criterion for this last exclusion was arbitrarily predefined as the concentration 24 hours after trial medication intake (CFor TAF, we compared our observed geometric mean (GM) of AUCFor TFV, we aimed for the GM AUC